(Q42281646)

English

Elevated risk of opportunistic viral infection in patients with Crohn's disease during biological therapies: a meta analysis of randomized controlled trials

scientific article published on 25 July 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

0 references

Elevated risk of opportunistic viral infection in patients with Crohn's disease during biological therapies: a meta analysis of randomized controlled trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Crohn's disease

1 reference

based on heuristic

inferred from title

author name string

Xiaobing Wang

1

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Feng Zhou

2

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Junzhang Zhao

3

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Rui Zhou

4

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Meifang Huang

5

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Jin Li

6

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Wei Wang

7

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Shufang Xu

8

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Bing Xia

9

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

publication date

25 July 2013

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

European Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

69

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

1891-1899

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

https://scigraph.springernature.com/pub.10.1007/s00228-013-1559-8

0 references

Long-term evolution of disease behavior of Crohn's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Crohn's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Role of conventional therapies in the era of biological treatment in Crohn's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Conventional medical management of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Natalizumab for active Crohn's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Adalimumab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Certolizumab pegol for the treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Infliximab maintenance therapy for fistulizing Crohn's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Risk factors for opportunistic infections in patients with inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Review article: targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease--the mechanisms of action of infliximab

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

The pathophysiologic role of alpha 4 integrins in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Role of integrin alpha 4 beta 7/alpha 4 beta P in lymphocyte adherence to fibronectin and VCAM-1 and in homotypic cell clustering

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

PI3K p110beta positively regulates lipopolysaccharide-induced IL-12 production in human macrophages and dendritic cells and JNK1 plays a novel role

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Genetic polymorphism of IL-12 p40 gene in immune-mediated disease.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

An interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Crohn's disease and experimental colitis in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

IL-23/IL-17 axis in IBD.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Interleukin-23 drives intestinal inflammation through direct activity on T cells

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

Infliximab, azathioprine, or combination therapy for Crohn's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1559-8

21 January 2018

A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23884581

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23884581

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23884581

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23884581

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maintenance therapy with certolizumab pegol for Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23884581

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23884581

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00228-013-1559-8

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

release_ug6qnsshifdsviisgcl6qpdxzi

1 reference

https://api.fatcat.wiki/v0/release/ug6qnsshifdsviisgcl6qpdxzi

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42281646&oldid=1940996254"